The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall

Eurointervention 2019; publish-ahead-of-print Jun 2019. DOI: 10.4244/EIJY19M06_1

1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington DC, USA
Drug-coated balloons (DCB) and stents with paclitaxel were introduced to treat superficial femoropopliteal artery (SFA) lesions in patients with claudication and/or critical limb ischaemia. Randomised controlled trials (RCTs) demonstrated reduction of restenosis and need for revascularisation for DCB in comparison with plain balloons and bare metal stents and were approved for marketing use in the USA by the Food and Drug Administration (FDA) in 2012. Specifically, multiple RCTs and registries evaluating the treatment of the SFA lesions in patients with claudication have shown the effectiveness of paclitaxel drug-coated balloons (P-DCB) and paclitaxel drug-eluting stents (P-DES). However, there have been conflicting ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Are we too simple in planning complex structural interventions? The potential role of cardiac computed tomography to prepare for percutaneous left atrial appendage closure